Retatrutide Timeline, Clinical Data, and Regulatory Outlook

On July 23, 2026, Eli Lilly announced it will file a Biologics License Application (BLA) for retatrutide with the FDA in Q1 2027, after completing five positive Phase 3 trials . The company had previously guided for a 2026 submission, but the timeline was pushed to early 2027 to incorporate the full data package .

FDA Filing & Commercialization Timeline

• BLA submission to FDA: Planned Q1 2027
• Standard FDA review period: ~10–12 months, which would place an approval decision around late 2027 to early 2028
• Commercial launch (if approved): Estimated Q1–Q2 2028, roughly 1–3 months post-approval

Note: Earlier industry estimates had assumed a Q4 2026 NDA submission leading to late 2027 approval . Lilly's new Q1 2027 filing target pushes the likely approval window into 2028.

TRIUMPH-2 Results (Obesity + Type 2 Diabetes)

• Population: 1,152 adults with obesity or overweight plus type 2 diabetes
• Primary endpoint met: Mean weight loss of 12.7%–20.8% across the 4–12 mg retatrutide doses at 80 weeks, vs. 4.0% with placebo
• Glycemic efficacy: A1C reductions of up to 1.6 percentage points from a 7.7% baseline, vs. 0.2 percentage points with placebo
• Additional metabolic benefits: Improvements in waist circumference, fasting glucose, triglycerides (~41%), and blood pressure were also reported

TRIUMPH-3 Results (Obesity + Established Cardiovascular Disease)

• Population: Adults with obesity or overweight and established cardiovascular disease
• Weight loss: Both studied doses (9 mg and 12 mg) delivered "substantial" weight loss, meeting the primary endpoint . A press release from Lilly noted participants lost up to an average of 55.8 lbs (22.6%) at 80 weeks .
• Cardiometabolic data: Lilly presented detailed Phase 3 data for retatrutide in type 2 diabetes at ADA 2026, showing up to 85% of treated participants reaching an A1C target of ≤6.5% and 46% achieving normoglycemia (A1C <5.7%) .

Cardiovascular Outcomes Data — Important Nuance

This is the key area where clarity is needed:

• TRIUMPH-3 is a weight management efficacy trial in patients with existing CVD, not a dedicated cardiovascular outcomes trial (CVOT) . It was designed to evaluate weight loss and safety in a higher-risk population, but its 80-week duration is insufficient for definitive MACE (major adverse cardiovascular events) adjudication .
• The dedicated CVOT — TRIUMPH-CVOT (TRIUMPH-5) — remains ongoing, with a primary MACE endpoint (cardiovascular death, myocardial infarction, stroke) and an expected completion around 2028–2029 .
• What this means: There are no definitive long-term cardiovascular outcomes data for retatrutide yet. TRIUMPH-3 provides short-term safety data in a CVD population, but the question of whether retatrutide reduces or increases cardiovascular events beyond what its weight-loss effect would predict remains unanswered until the CVOT reads out.

Summary of All TRIUMPH Phase 3 Program Results

Trial	Population	Key Weight Loss Result (80 weeks)	Status
TRIUMPH-1	Obesity/overweight, no T2D	28.3% (12 mg); 45.3% achieved ≥30%	Positive (May 2026)
TRIUMPH-2	Obesity/overweight + T2D	12.7%–20.8% across doses	Positive (July 2026)
TRIUMPH-3	Obesity/overweight + CVD	Substantial at both 9 mg & 12 mg	Positive (July 2026)
TRIUMPH-4	Obesity + knee OA	28.7% at 68 weeks (12 mg)	Positive (Dec 2025)
TRIUMPH-CVOT (5)	CV/renal outcomes	MACE endpoints	Ongoing, ~2028–2029

Lilly stated that with TRIUMPH-2 and TRIUMPH-3 complete, it now has the data package needed to pursue global regulatory submissions for obesity, knee osteoarthritis, obstructive sleep apnea, and weight management with type 2 diabetes .